VEGFA and glioma: Elevated levels of VEGF in serum/plasma of patients with gliomas seem to correlate with the microvascular density of the tumoral lesions 23 and current trials on GBMs with antiangiogenic agents, have shown a higher response rate and 6‐month progression free survival 24, but rather modest effects on overall survival 25.